Biological Background of CPEB1

Cytoplasmic Polyadenylation Element Binding Protein 1 (CPEB1) is the founding member of the conserved CPEB family of RNA-binding proteins. CPEB1 recognizes and binds to cytoplasmic polyadenylation elements (CPEs), which are uridine-rich sequences located in the 3′ untranslated regions (3′ UTRs) of target mRNAs. Through this interaction, CPEB1 orchestrates the cytoplasmic elongation or shortening of poly(A) tails, thereby controlling the translational status of a defined subset of transcripts.

CPEB1 is particularly well characterized in two biological contexts. First, during oocyte maturation, CPEB1 coordinates the translational activation of maternal mRNAs encoding key cell-cycle regulators such as cyclin B1, enabling meiotic progression. Second, in the nervous system, CPEB1 regulates activity-dependent local translation at synapses, a process implicated in long-term memory consolidation and synaptic plasticity. Beyond these canonical roles, emerging research links CPEB1 dysregulation to cancer cell proliferation, senescence, and metastasis, positioning this protein as a candidate therapeutic target.

The human CPEB1 protein contains two RNA recognition motifs (RRMs) and a conserved zinc-finger domain in its C-terminal region that mediate high-affinity CPE binding, while an N-terminal regulatory domain integrates upstream kinase signals, including phosphorylation by Aurora A kinase, to toggle its activating and repressive functions.

Protein Specifications and Quality Considerations

Recombinant Human CPEB1 Protein (SKU: rp189330) is produced using recombinant expression technology and is intended for in vitro research use. When evaluating this reagent for your experimental workflow, the following quality parameters are important to confirm with the product datasheet prior to use:

• Expression System: Confirm the host expression system (e.g., E. coli, baculovirus/insect cell, or mammalian HEK293) as this influences post-translational modifications, folding, and suitability for specific assays.
• Purity: High-purity preparations (typically ≥85–90% by SDS-PAGE) are recommended for functional assays, pull-down experiments, and structural studies. Verify purity specification on the certificate of analysis (CoA).
• Tag and Tag Removal: Many recombinant CPEB1 preparations carry an affinity tag (His, GST, or FLAG) that facilitates purification. Confirm whether a tag is present and whether tag removal options are available if the tag may interfere with downstream assays.
• Activity Validation: Confirm whether RNA-binding activity or functional assay data are provided with the lot.
• Endotoxin Level: For cell-based experiments, verify that endotoxin levels are within acceptable limits (typically <1.0 EU/μg).

Always consult the product-specific datasheet and CoA supplied with each lot before initiating experiments, as specifications may vary between production lots.

Handling, Storage, and Reconstitution Protocol

Proper handling of Recombinant Human CPEB1 Protein is critical to maintaining its structural integrity and functional activity. Follow the guidelines below to maximize reagent performance and reproducibility:

1. Upon Receipt: Immediately record the lot number and inspect the packaging. If the protein is supplied lyophilized, confirm the vial is intact and vacuum-sealed. If supplied as a liquid, verify the sample remained frozen during transit.
2. Storage: Store lyophilized protein at −20 °C to −80 °C in a desiccated environment. Store liquid formulations at −80 °C. Both formats should be protected from light.
3. Reconstitution (Lyophilized Form): Allow the vial to equilibrate to room temperature before opening to minimize moisture condensation. Reconstitute in the buffer specified on the datasheet — typically sterile deionized water or a low-salt buffer (e.g., PBS, pH 7.4) supplemented with a carrier protein such as 0.1% BSA to improve stability. Add reconstitution buffer gently along the vial wall; do not vortex. Mix by gentle pipetting and allow to dissolve for 5–10 minutes at room temperature.
4. Aliquoting: Prepare single-use aliquots immediately after reconstitution to avoid repeated freeze-thaw cycles, which can degrade protein structure and reduce activity. Use low-protein-binding microcentrifuge tubes.
5. Freeze-Thaw Cycles: Limit to a maximum of 2–3 freeze-thaw cycles. Each additional cycle increases the risk of aggregation and loss of RNA-binding function.
6. Working Concentration: Determine the optimal working concentration empirically for each assay type. Begin with the concentration range recommended in the product datasheet as a starting point.

Note: All specific buffer compositions, reconstitution volumes, and storage temperatures should be verified against the lot-specific datasheet provided with product rp189330, as formulations may be updated.

Experimental Applications of Recombinant Human CPEB1 Protein

Recombinant Human CPEB1 Protein is suited to a range of in vitro research applications. Representative uses include:

• RNA Electrophoretic Mobility Shift Assay (EMSA): CPEB1 can be used to assess binding affinity and specificity to CPE-containing RNA probes derived from known target mRNAs such as cyclin B1 3′ UTR. EMSA enables qualitative and quantitative characterization of protein–RNA interactions.
• RNA Pull-Down Assays: Biotinylated RNA oligonucleotides harboring CPE sequences can be used to capture recombinant CPEB1 from solution, enabling confirmation of binding and identification of co-interacting factors.
• In Vitro Binding and Competition Assays: Recombinant CPEB1 supports competitive binding experiments to evaluate small-molecule inhibitors or peptides targeting the RNA-binding interface, useful in early-stage drug discovery campaigns.
• Antibody Validation and Immunoassay Standards: Purified recombinant CPEB1 can serve as a positive control or calibration standard in Western blot, ELISA, or immunoprecipitation experiments.
• Structural and Biophysical Studies: The protein can be used in surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence polarization assays to determine binding kinetics and thermodynamic parameters of CPEB1–RNA or CPEB1–protein interactions.
• In Vitro Phosphorylation Assays: Recombinant CPEB1 can serve as a substrate for kinases such as Aurora A to study phosphorylation-dependent conformational changes and functional switching.

Researchers should optimize assay conditions — including buffer composition, protein concentration, incubation time, and temperature — empirically for each application.

Troubleshooting Common Issues

The following table outlines common challenges encountered when working with Recombinant Human CPEB1 Protein and suggested corrective actions:

• Protein Precipitation or Aggregation: Caused by freeze-thaw damage, incompatible buffer conditions, or excessive concentration. Remedies include centrifuging the sample at 10,000 × g for 5 minutes to remove aggregates, reducing working concentration, adding 5–10% glycerol or 0.1% BSA as stabilizers, and ensuring gentle mixing without vortexing during handling.
• Weak or No Signal in EMSA / Pull-Down: May indicate loss of RNA-binding activity due to improper storage or handling. Verify storage conditions, use a fresh aliquot, confirm that RNA probes contain a validated CPE sequence, and check that salt concentrations in the binding buffer are appropriate (typically 50–150 mM NaCl for CPEB1-RNA interactions).
• Non-Specific Bands in Western Blot: Can arise from degradation products or bacterial contaminants in the preparation. Optimize antibody dilutions, include a protease inhibitor cocktail during sample preparation, and consult the CoA for expected molecular weight.
• Inconsistent Results Between Experiments: Most frequently attributable to variable numbers of freeze-thaw cycles. Standardize by pre-aliquoting and tracking freeze-thaw history for each vial. Confirm lot-to-lot consistency by including an internal positive control in each experiment.
• Lower-Than-Expected Activity in Kinase Assays: Verify that the recombinant protein is not already phosphorylated from the expression system. Consider using a phosphatase treatment step prior to the assay to obtain a defined starting phosphorylation state.